Ratio Therapeutics' $70M Raise Is Not About Drug Discovery

Ratio Therapeutics closed a $70 million Series C on July 31. The press release calls it financing to advance cancer radiotherapy. That's not wrong, but it doesn't tell you what's actually happening.

The harder problem in radiopharmaceuticals isn't finding a molecule that binds to cancer cells. It's getting enough radioactive isotope to make the drug. Actinium-225, the isotope Ratio's lead candidate uses, was so scarce in 2024 that Bristol Myers Squibb... had to pause a Phase 3 trial because there wasn't enough to go around. The worldwide supply that year was estimated at about 2 curies, enough to treat roughly 2,000 patients.

This is the supply chain story disguised as a drug discovery story. And it's the one investors should be reading.

Radiopharmaceuticals are drugs that carry a radioactive isotope to a tumor and destroy it from the inside. Alpha emitters like actinium-225 are especially attractive because they deposit a lot of energy over a very short distance - fewer than ten cell diameters. They're surgical at the molecular level. But actinium-225 doesn't occur naturally. It comes from thorium-229, which comes from uranium-233 stockpiles leftover from 1950s atomic weapons programs. Oak Ridge National Laboratory has been the main supplier for nearly thirty years, and demand has far outpaced their ability to increase output.

New producers are coming online through different physical processes: TerraPower is taking the thorium-229 recovery route, while BWXT, NorthStar, and Niowave are pursuing accelerator- and cyclotron-based routes. But the timeline to commercial-scale, regulatory-quality supply is measured in years, not quarters. That's why pharma companies are locking in supply agreements before they even know whether their drugs will work. AstraZeneca signed a ten-year deal with Niowave last December. Eli Lilly invested in Ionetix, a cyclotron manufacturer.

Ratio has been doing something similar. In the second quarter of 2026, they locked in dedicated actinium-225 supply from PanTera. In the year before the June 2025 Macrocyclics deal, they focused on cultivating scientific awareness around Macropa, their proprietary chelator - the chemical "glue" that binds the radioactive isotope to the targeting molecule. In June 2025, they granted Macrocyclics exclusive global rights to manufacture and distribute Macropa. Researchers at universities and other pharma companies can now buy it directly. That's not a drug pipeline move. That's building a toll road.

The investor list reinforces the picture. Bristol Myers Squibb participated in this round. So did Eli Lilly. Both companies have their own actinium-225 programs and know what the supply bottleneck feels like. They're not just buying shares in Ratio's lead molecule. They're investing in the infrastructure that makes any Ac-225 program possible.

Duquesne Family Office, an existing investor, called Ratio a "leader in radiopharmaceutical innovation" that has "backed up science with execution". The execution they're referring to isn't just the ATLAS trial - Ratio completed first-cohort dosing in December 2025, testing their FAP-targeted compound in advanced sarcomas. It's the vertically integrated manufacturing site in Utah, the hybrid supply model with external partners, the diversified isotope sourcing. The kind of things that don't show up in a molecule structure but determine whether a drug can actually reach patients.

There's a risk here, and it's the standard one for early-stage clinical biotech. The ATLAS trial is in Phase 1/2. The first cohort was dosed less than eight months ago. We don't know whether RTX-2358 will show durable responses in the trial. Ratio's platform advantages - pharmacokinetic tuning through their Trillium scaffold, Macropa's room-temperature labeling - are real, but they're not enough if the clinical data doesn't support it.

The way to think about this financing is not as a bet on whether Ratio's drug will work. It's a bet on whether the actinium-225 supply chain will clear the bottleneck before the companies riding it run out of money. New Ac-225 production capacity is coming online, but the gap between clinical need and available supply is still large. Ratio has $240 million in total capital raised, which should carry them through multiple IND filings - they're preparing a fifth - and into Phase 2 data.

What to watch: whether the broader Ac-225 supply picture improves over the next twelve months, and whether Ratio's ATLAS trial shows enough signal in sarcoma to justify the expansion phase. If the supply chain stays tight and the data is encouraging, the manufacturing and platform plays become more valuable than the individual drug candidates. If supply eases and the data is disappointing, the opposite is true. The test is simple - the supply chain is the leading indicator, and the trial is the laggard.